BlackRock targets stablecoin boom with new fund

ambcryptoPubblicato 2025-10-16Pubblicato ultima volta 2025-10-16

Key Takeaways

What is BlackRock’s new fund targeting?

BlackRock has launched the Select Treasury Based Liquidity Fund for stablecoin issuers.

Why does it matter for the stablecoin market?

The fund cements BlackRock’s position as a top reserve manager for stablecoin providers, offering liquidity and GENIUS Act compliance.


BlackRock is taking a major step deeper into digital assets, launching a retooled money market fund.

According to a CNBC report, the fund is designed for stablecoin issuers as global stablecoin supply surges to an all-time high.

Also, the new product, the BlackRock Select Treasury Based Liquidity Fund [BSTBL], aims to help issuers manage reserves more efficiently under the GENIUS Act. 

The landmark U.S. legislation was signed by President Donald Trump months ago and created the country’s first federal framework for stablecoins.

BlackRock said the BSTBL fund now offers greater liquidity, expanded trading hours, and full compliance with the new stablecoin standards.

The move positions it to become the go-to reserve manager for the next wave of stablecoin providers.

BlackRock’s stablecoin playbook

BlackRock already oversees Circle’s $64 billion USDC reserve portfolio. It helped push its cash-management business above $1 trillion in assets last quarter. 

With the updated BSTBL fund, the firm plans to bring the same model to other issuers. Also, it offers secure, yield-bearing exposure to short-term U.S. Treasurys and government securities.

Furthermore, the launch comes as the stablecoin supply reaches a record $302.3 billion, according to recent data.

Stablecoin supplyStablecoin supply

Source: X

According to CryptoRank, new entrants such as USDe, USD1, and PYUSD are fueling adoption as institutional capital floods in.

Why it matters

BlackRock’s pivot reflects how Wall Street is moving from merely investing in crypto to powering its core financial infrastructure. 

Stablecoins are increasingly used to settle trades, provide collateral, and transfer value across blockchains—functions that demand the kind of liquidity management BlackRock specializes in.

With the GENIUS Act’s clarity and its partnership track record, BlackRock is now positioned to capture a large share of that growth.

The bigger picture

BlackRock’s latest move extends its crypto presence beyond ETFs and tokenized funds like BUIDL.

As the stablecoin market breaks new records, BlackRock is no longer just offering exposure to crypto; it’s becoming part of the system’s foundation.

Share

Letture associate

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

On August 18th, Haowei Huaxin, a semiconductor firm specializing in gallium arsenide and gallium nitride wafers, reported that over a hundred individuals forcibly entered its offices and seized the company's official seals from a safe, including the corporate, contract, and party committee seals. The incident is the latest escalation in a protracted control dispute. Haowei Huaxin, established in 2010, was originally a joint venture. Control became contested after 2021 when Zhenwei Financial Holding injected capital, becoming the largest shareholder (34.01%), while former parent Haite High-Tech's stake was diluted to 33.79%. An agreed-upon governance structure collapsed, leading to mutual accusations. Haite claimed it was locked out of the subsidiary's premises, while also alleging improper management like livestock being kept on the chip fabrication site. After state-owned Qingdao Haiyue Holdings took over Zhenwei's stake in 2023, Haite accused it of illegally seizing control. Despite Haite winning several legal battles in 2024-2026, which affirmed its rights to nominate directors and the chairman, it failed to regain physical control or recover the seals. The stakes are high: market valuations for Haite's stake in Haowei Huaxin are estimated between 3.7 to 5 billion USD, yet it is only valued at about 83 million USD on Haite's books. Losing control effectively jeopardizes a significant portion of Haite's value. In response to the seal seizure, Haite framed it as a "shareholder rights protection" action agreed upon by five shareholders. This mirrors a pattern in Chinese corporate disputes where seizing physical seals becomes a tactic to paralyze the opponent's daily operations, seen in past conflicts at companies like Dangdang and Bitmain. However, such actions don't resolve underlying ownership issues; the opposing party can report the seals stolen, declare them void, and apply for new ones, albeit with significant delay. The incident underscores how fragile corporate governance can devolve into physical confrontations over symbols of authority, with control ultimately determined by law and shareholding, not possession of a seal.

marsbit27 min fa

Haiwei Huaxin's Official Seal Seized by Over a Hundred People, High-Stakes Corporate Battle's 'Nuclear Deterrence' in Action Again

marsbit27 min fa

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

Bernstein's analysis of Moderna's 177% stock surge following positive Phase 3 results for its individualized neoantigen therapy (INT) in melanoma distinguishes fundamental drivers from market speculation. The clinical breakthrough is real: the INTerpath-001 trial met its primary and key secondary endpoints, providing crucial validation for mRNA technology in oncology beyond infectious diseases. However, Bernstein argues the magnitude of the stock move cannot be justified by this single trial's fundamentals alone. The surge was amplified by three key factors: 1) A re-rating of Moderna's mRNA platform potential for expansion into other cancers, 2) A massive short squeeze, given ~15% of shares were sold short pre-announcement, and 3) The compelling "cancer vaccine" narrative that fueled broader investor enthusiasm. While the melanoma success is significant, Bernstein cautions that replication in lung, kidney, and bladder cancers—which have different immunogenicity—is not guaranteed. Furthermore, INT's commercial model faces challenges: it's a personalized treatment, not a mass-market vaccine, implying higher production costs and potential margin pressures despite a projected multi-billion dollar peak sales opportunity. The report also notes sector rotation, with some funds moving from crowded AI/semiconductor trades into defensive healthcare stocks, adding further momentum. In conclusion, Bernstein maintains a "Market-Perform" rating and a $45 price target, far below the post-surge price. It views the current valuation as pricing in an optimistic multi-cancer platform success and efficient commercialization that are yet to be proven. The clinical inflection point is clear, but the earnings inflection point awaits validation across future trials and commercial execution.

marsbit27 min fa

Bernstein Interprets MRNA's 177% Surge: What's Fundamentals and What's Hype?

marsbit27 min fa

Trading

Spot
活动图片